查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869760

美國氣喘藥物市場規模、佔有率和趨勢分析報告：按藥物類別、醫療設備類型、給藥途徑、產品和細分市場預測（2025-2033 年）

U.S. Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory, Bronchodilators), By Device Type (Inhalers, Nebulizers), By Route of Administration (Oral, Inhaled), By Product, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

據估計，美國氣喘藥物市場在 2024 年的價值為 130 億美元，預計到 2033 年將達到 192 億美元。

預計從 2025 年到 2033 年，氣喘市場將以 4.5% 的複合年成長率成長。隨著美國氣喘患者人數的增加，對有效治療方法（包括前沿和有前景的治療方法）的需求也日益成長。

受氣喘病例不斷增加的推動，美國氣喘藥物市場呈現穩定成長態勢。根據美國肺臟協會統計，美國有超過2500萬人患有氣喘，其中約5%至10%被診斷為重度氣喘。這凸顯了對更有效、更有針對性的治療方法的迫切需求。儘管目前已有多種治療方法，但許多患者仍頻繁遭受氣喘發作的困擾，這也暴露出現有藥物的限制。為此，製藥公司正加大投入，研發能夠提供更有針對性、更有效解決方案的先進治療方法。

2023年2月，安進和Astra Zeneca宣布，TedSpire獲得美國食品藥物管理局（FDA）核准，用於治療12歲以上重度氣喘患者。該藥物已核准在美國使用預預填充筆自我給藥。此外，該藥物還在美國、日本、歐盟和其他國家核准。

精準醫療和個人化治療方案的日益普及正在顯著改變美國的氣喘治療模式。隨著醫療保健朝著更個人化的方向發展，人們對生物標記和基因譜分析的興趣日益濃厚，希望利用它們來有效指導治療決策。這種轉變使醫生能夠為每位患者確定氣喘的真正病因，並選擇最有效的治療方法。此外，人工智慧 (AI) 和數據分析正被整合到臨床實踐中。這種整合提高了治療監測的準確性和診斷精度。這些臨床和技術進步不僅改善了治療效果，也為新的藥物創新創造了機遇，有望推動美國氣喘治療市場持續創新主導成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章：美國氣喘藥物市場的趨勢與展望

  • 市場體系展望
    • 母市場
    • 子公司市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國氣喘藥物市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析
    • 法律規範

第4章美國氣喘藥物市場：藥物類別估算與趨勢分析

  • 細分儀表板
  • 美國氣喘藥物市場：藥物類別差異分析
  • 美國氣喘藥物市場規模及趨勢分析（依藥物類別分類，2021-2033 年）
  • 消炎（藥）
  • 支氣管擴張劑
  • 聯合療法

第5章美國氣喘藥物市場：器械類型估算與趨勢分析

  • 細分儀表板
  • 美國氣喘藥物市場：器材類型差異分析
  • 美國氣喘藥物市場規模及趨勢分析（依器材類型分類），2021-2033年
  • 吸入器
  • 噴霧器

第6章：美國氣喘藥物市場：產品估算與趨勢分析

  • 細分儀表板
  • 美國氣喘治療市場（依產品分類）
  • 美國氣喘藥物市場規模及趨勢分析（依產品分類，2021-2033 年）
  • 乾粉
  • 計量噴霧型
  • 緩霧

第7章美國氣喘藥物市場：給藥途徑估算與趨勢分析

  • 細分儀表板
  • 美國氣喘藥物市場：給藥途徑差異分析
  • 美國氣喘藥物市場規模及趨勢分析（依給藥途徑分類，2021-2033 年）
    • 口服
    • 吸入
    • 靜脈

第8章 競爭情勢

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 公司簡介
    • Teva Pharmaceuticals Industries Ltd.
    • GSK plc
    • Merck &Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • Covis Pharma
    • Pfizer
    • Regeneron
    • Amgen
Product Code: GVR-4-68040-778-4

Market Size & Trends:

The U.S. asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The rising number of asthma patients in the U.S. has led to a growing demand for effective therapies, including some of the most advanced and promising treatment options.

The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.

In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.

The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.

U.S. Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. asthma therapeutics market report based on drug class, device type, product, route of administration.

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Anti- inflammatory
  • Bronchodilators
  • Combination therapy
  • Device Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Inhalers
  • Nebulizers
  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Dry Powder
  • Metered Dose
  • Soft Mist
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Inhaled
  • Intravenous

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Regional Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Asthma Therapeutics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Asthma Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework

Chapter 4. U.S. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Asthma Therapeutics Market: Drug Class Movement Analysis
  • 4.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Anti-inflammatory
    • 4.4.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Bronchodilators
    • 4.5.1. Bronchodilators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Combine Therapy
    • 4.6.1. Combine Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Asthma Therapeutics Market: Device Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Asthma Therapeutics Market: Device Type Movement Analysis
  • 5.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Device Type, 2021 to 2033 (USD Billion)
  • 5.4. Inhalers
    • 5.4.1. Inhalers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Nebulizers
    • 5.5.1. Nebulizers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Asthma Therapeutics Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Asthma Therapeutics Market by Product
  • 6.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
  • 6.4. Dry Powder
    • 6.4.1. Dry Powder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Metered Dose
    • 6.5.1. Metered Dose Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Soft Mist
    • 6.6.1. Soft Mist Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Asthma Therapeutics Market: By Route of Administration Movement Analysis
  • 7.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
    • 7.3.1. Oral
      • 7.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.2. Inhaled
      • 7.3.2.1. Inhaled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.3. intravenous
      • 7.3.3.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Teva Pharmaceuticals Industries Ltd.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Application Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. GSK plc
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Application Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Merck & Co. Inc.
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. F. Hoffmann-La Roche Ltd
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Boehringer Ingelheim International GmbH
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sanofi
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Koninklijke Philips N.V.
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Covis Pharma
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Pfizer
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Regeneron
      • 8.3.11.1. Participant's Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Amgen
      • 8.3.12.1. Participant's Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 U.S. Asthma Therapeutics Market, by Drug Class, 2021 - 2033 (USD Billion)
  • Table 3 U.S. Asthma Therapeutics Market, by Device Type, 2021 - 2033 (USD Billion)
  • Table 4 U.S. Asthma Therapeutics Market, by Product, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Asthma Therapeutics Market, by Route of Administration, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modelling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 U.S. Asthma Therapeutics Market Revenue, 2021-2033 (USD Billion)
  • Fig. 10 U.S. Asthma Therapeutics Market Snapshot
  • Fig. 11 U.S. Asthma Therapeutics Market Driver Impact
  • Fig. 12 U.S. Asthma Therapeutics Market Restraint Impact
  • Fig. 13 U.S. Asthma Therapeutics Product Key Takeaways (USD Billion)
  • Fig. 14 U.S. Asthma Therapeutics Market: Product Movement Analysis
  • Fig. 15 Drug Class Market, 2021 - 2033 (USD Billion)
  • Fig. 16 Anti-inflammatory Market, 2021 - 2033 (USD Billion)
  • Fig. 17 Bronchodilators Market, 2021 - 2033 (USD Billion)
  • Fig. 18 Combination Therapy Market, 2021 - 2033 (USD Billion)
  • Fig. 19 U.S. Asthma Therapeutics Device Type Key Takeaways (USD Billion)
  • Fig. 20 U.S. Asthma Therapeutics Market: Device Type Movement Analysis
  • Fig. 21 Inhalers Market, 2021 - 2033 (USD Billion)
  • Fig. 22 Nebulizers Market, 2021 - 2033 (USD Billion)
  • Fig. 23 U.S. Asthma Therapeutics Market: Product Movement Analysis
  • Fig. 24 Dry Powder Market, 2021 - 2033 (USD Billion)
  • Fig. 25 Metered Dose Market, 2021 - 2033 (USD Billion)
  • Fig. 26 Soft Mist Market, 2021 - 2033 (USD Billion)
  • Fig. 27 U.S. Asthma Therapeutics Market Route of Administration Key Takeaways (USD Billion)
  • Fig. 28 U.S. Asthma Therapeutics Market: Route of Administration Movement Analysis
  • Fig. 29 Oral Market, 2021 - 2033 (USD Billion)
  • Fig. 30 Inhaled Market, 2021 - 2033 (USD Billion)
  • Fig. 31 Intravenous Market, 2021 - 2033 (USD Billion)